Abstract

Objectives: To measure plasma concentrations of Tumor Necrosis Factor Receptor 2 in patients with acute leukemia, and to correlate the results with clinical features.
Material and Methods: Twenty-four patients with acute myeloid leukemia (AML), sixteen patients with acute lymphoblastic leukemia (ALL) and fifteen control subjects were included in the current study. Tumor Necrosis Factor Receptor 2 was measured in plasma of all subjects by enzyme-linked immunosorbent assay.
Results: Plasma Tumor Necrosis Factor Receptor 2 significantly increased in ALL compared to both control and AML cases.
Conclusions: TNFR2 may be used as a biomarker for differentiating between AML and ALL patients.

Key words: Tumor Necrosis Factor Receptor 2, Acute leukemia, Myeloid, Lymphoblastic